Darovasertib data are promised for the last week of March.
ApexOnco Front Page
Recent articles
Just like other oral SERDs, filing is restricted to the ESR1-mutant population.
The end of three licensed assets sees Takeda take a step back from autologous cell therapy.
Rusfertide’s big readout will now not come until 2025.
A third discontinuation leaves one anti-FAP project in Roche’s clinical pipeline.
The company’s move could be a warning for rivals including GSK, AstraZeneca and Incyte.
First-in-human trial initiations feature anti-PSMA radioligands, KRAS G12D, Nectin-4 and more.
The group’s B7-H4-targeting bispecific is out, in favour of Seagen’s ADC.